STADA seeks to strengthen its equity base
09/22/2003 . Ad hoc Release
The executive board of STADA Arzneimittel AG resolved today, with the approval of the supervisory board, to effect an increase in the share capital this year with an anticipated value of EUR 250 to 350 million, to strengthen its equity base. STADA intends to use the proceeds from the capital increase to finance further internal and external growth, for the partial repayment of liabilities and for general business purposes within STADA Arzneimittel AG and the Group. Deutsche Bank AG, in its capacity as the Global Coordinator, will render assistance in effecting the capital increase.
The capital increase is intended to comprise of two tranches. The first tranche consisting of 5,000,000 new shares is intended to be effected as a capital increase together with subscription rights of the shareholders in the ratio 4:1. Subject to the final approval of executive board and supervisory board, it is currently intended to offer the shares for subscription during the period from September 30 through October 13, 2003. Within the framework of the capital increase, excluding subscription rights, in the second tranche, up to approximately 1,680,000 new shares and by way of over-allotment up to 186,000 shares of STADA Arzneimittel AG are intended to be placed with investors within Germany and abroad. With regard to the over-allotment the banks aregranted a purchase option (so-called Greenshoe). The details of the capital increase will be provided shortly before the issue and will be provided subject to the current market situation.
For more information, please contact:
STADA Arzneimittel AG
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506